Virios Therapeutics, Inc. (VIRI) is a publicly traded company in the Unknown sector. Across all available filings, 7 corporate insiders have executed 29 transactions totaling $609.4K, demonstrating a bullish sentiment with $608.5K in net insider flow. The most recent transaction on Aug 21, 2023 involved a purchase of 15,335 shares valued at $19.9K.
No significant insider buying has been recorded for VIRI in the recent period.
No significant insider selling has been recorded for VIRI in the recent period.
Based on recent SEC filings, insider sentiment for VIRI is bullish with an Insider Alignment Score of 100/100 and a net flow of $608.5K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Virios Therapeutics, Inc. (VIRI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 7 insiders are actively trading VIRI stock, having executed 29 transactions in the past 90 days. The most active insider is Gregory Scott Duncan (Executive), who has made 7 transactions totaling $294.9K.
Get notified when executives and directors at VIRI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 21, 2023 | Pridgen William | Executive | Purchase | 15,335 | $1.30 | $19.9K | |
| Aug 17, 2023 | Scott Duncan Gregory | Executive | Purchase | 25,000 | $1.25 | $31.3K | |
| Dec 8, 2022 | James Whitley Richard | Executive | Sale | 1,800 | $0.26 | $468 | |
| May 23, 2022 | Scott Duncan Gregory | Executive | Purchase | 7,500 | $4.52 | $33.9K | |
| May 23, 2022 | Walsh Angela | Executive | Purchase | 2,000 | $4.58 | $9.2K | |
| May 18, 2022 | Pridgen William | Executive | Purchase | 241 | $4.50 | $1.1K | |
| May 18, 2022 | James Whitley Richard | Executive | Purchase | 500 | $4.53 | $2.3K | |
| May 17, 2022 | Pridgen William | Executive | Purchase | 13,450 | $4.38 | $58.9K | |
| Mar 29, 2022 | Pridgen William | Executive | Purchase | 600 | $4.94 | $3.0K | |
| Mar 23, 2022 | Pridgen William | Executive | Purchase | 2,197 | $5.46 | $12.0K | |
| Jan 27, 2022 | Pridgen William | Executive | Purchase | 4,180 | $5.98 | $25.0K | |
| Jan 7, 2022 | Rosa Abel De La | Executive | Purchase | 4,000 | $5.90 | $23.6K | |
| Jan 6, 2022 | James Whitley Richard | Executive | Purchase | 1,800 | $5.72 | $10.3K | |
| Jan 4, 2022 | C. Thomas John | Executive | Purchase | 1,000 | $5.65 | $5.7K | |
| Jan 4, 2022 | R. Keefer David | Executive | Purchase | 5,000 | $5.80 | $29.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 25 | $609.0K | 96.0% |
Exercise(M) | 3 | $25.0K | 3.9% |
Sale(S) | 1 | $468 | 0.1% |
Insiders at Virios Therapeutics, Inc. are accumulating shares at an accelerated pace. With 7 insiders making 29 transactions totaling $609.0K in purchases versus $468 in sales, the net buying activity of $608.5K signals strong executive confidence. Gregory Scott Duncan (Executive) leads the buying activity with $294.9K in transactions across all time.